Verona says FDA backs plan to take COPD drug into phase 3

More than two years after first saying it would take its lead drug into a pivotal trial, Verona Pharma looks like it may finally follow through on that promise.

Novartis on point in EU for asthma triple as CHMP backs Ener...

Chiesi starts rare diseases division, ahead of potential Fab...

Italian pharma Chiesi has begun a new rare diseases division as it builds towards a potential commercial launch for its Fabry Disease therapy.

FDA clears emergency diagnostic as coronavirus fears mount

FDA sets June date for latest review of Merck’s last-ditch a...

Chasing Mylan, Hikma tries again with rejected generic Advai...